Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 11:3:56-61.
doi: 10.1016/j.dib.2015.01.009. eCollection 2015 Jun.

A signature for immune response correlates with HCV treatment outcome in Caucasian subjects

Brian J Hare  1 , Eric Haseltine  1 , Mark Fleming  1 , Daniel Chelsky  2 , Laura McIntosh  2 , Rene Allard  2 , Martyn Botfield  1
Affiliations

A signature for immune response correlates with HCV treatment outcome in Caucasian subjects

Brian J Hare et al. Data Brief. .

Abstract

This data article contains Supplementary material for a published research article describing a whole-blood proteomic signature that predicts treatment outcome for subjects infected with hepatitis C virus (HCV) [1]. The proteomic signature is derived from whole-blood samples from subjects infected with HCV. The article includes detailed experimental and computational methods used in the analysis. The article also includes tables of demographic and other information about the subjects. Finally, the article includes several figures and tables showing detailed results of the analyses (e.g. lists of identified proteins and coefficients/ROC curves for the regression models).

PubMed Disclaimer

References

    1. B.J. Hare, E. Haseltine, M. Fleming, D. Chelsky, L. McIntosh, R. Allard, M. Botfield. A signature for immune response correlates with HCV treatment outcome in Caucasian subjects, 116 (2015) 59–67, http://dx.doi.org/10.1016/j.jprot.2014.12.015. - DOI - PubMed
    1. Gane E.J., Stedman C.A., Hyland R.H., Pang P.S., Ding X., Symonds W.T. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. J. Hepatol. 2013;58(Suppl 1):S6–S7.
    1. Kowdley K.V., Lawitz E., Poordad F., Cohen D.E., Nelson D., Zeuzem S. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/− Ribavirin in patients with chronic HCV GT1 infection: results from the aviator study. J. Hepatol. 2013;58(Suppl):S2.
    1. INCIVEK [US Prescribing Information]. No Title. 〈http://pi.vrtx.com/files/uspi_telaprevir.pdf〉, 2013.
    1. Sulkowski M.S., Ceasu E., Asselah T., Caruntu F.A., Lalezari J., Ferenci P. 60 SILEN-C1: Sustained Virologic Response (SVR) and safety of BI201335 combined with peginterferon alfa-2A and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection. J. Hepatol. 2011;54(Suppl):S27.

LinkOut - more resources